## We Claim:

1. A compound of the formula (I)

$$R^3$$

HN

 $R^2$ HNG

(1)

wherein  $R^1$  is a protecting group for  $N\alpha;$   $R^2 \text{ is a protecting group for } N_G; \text{ and }$   $R^3 \text{ is aryl; and }$ 

wherein the compound of formula (I) is a trypsin substrate such that trypsin cleaves the O-C single bond, which liberates  $R^3$ -OH.

- The compound of claim 1 wherein R<sup>1</sup> is selected from the group consisting of acyl, arene sulfonyl, and carbamoyl derivatives.
- The compound of claim 1 wherein R<sup>1</sup> is selected from the group consisting of t-butyloxycarbonyl and derivatives, benzyloxycarbonyl and derivatives, benzoyl and derivatives, and benzene sulfonyl and derivatives.
- $\label{eq:4.4} 4. \qquad \text{The compound of claim 1 wherein $R^2$ is selected from the group consisting of nitro, arene sulfonyl, carbamoyl, and acyl.}$
- The compound of claim 1 wherein R<sup>2</sup> is selected from the group consisting of nitro, benzene sulfonyl and derivatives, tosyl, carbobenzyloxy and derivatives, and benzoyl and derivatives.

MSE 2609

10

15

- The compound of claim 1 wherein R<sup>3</sup> comprises a heterocyclic aromatic molety.
  - 7. The compound of claim 6 wherein R<sup>3</sup> is a fused ring system.
  - 8. The compound of claim 1 wherein R<sup>3</sup> is carbocyclic.
- 9. The compound of claim 8 wherein R<sup>3</sup> is 1-naththol and derivatives thereof
- 10. The compound of claim 1 wherein R³ is selected from the group consisting of phenylpyrrole and derivatives thereof, coumarin and derivatives thereof, phenylthiophene and derivatives thereof, indole and derivatives thereof, and 2-phenyl-5H-thiazol and derivatives thereof.
- 11. The compound of claim 1 wherein R³-OH is optically distinct from the compound of formula (I).
  - 12. A diagnostic device comprising:
    - a carrier matrix; and
    - a compound of the formula (I)

$$R^{3}$$
 $R^{3}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{2}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{2}$ 
 $R^{4}$ 
 $R^{2}$ 
 $R^{4}$ 
 $R^{4}$ 

wherein  $R^1$  is a protecting group for  $N\alpha$ ;  $R^2$  is a protecting group for  $N_G$ ; and

MSE 2609

R3 is aryl; and

wherein the compound of formula (I) is a trypsin substrate such that trypsin cleaves the O-C single bond, which liberates R³-OH.

- 13. The diagnostic device of claim 12 wherein R<sup>1</sup> is selected from the group consisting of acyl, arene sulfonyl, and carbamoyl derivatives.
- 14. The diagnostic device of claim 12 wherein R¹ is selected from the group consisting of t-butyloxycarbonyl and derivatives, benzyloxycarbonyl and derivatives, benzoyl and derivatives, and benzene sulfonyl and derivatives.
- 15. The diagnostic device of claim 12 wherein R<sup>2</sup> is selected from the group consisting of nitro, arene sulfonyl, carbamoyl, and acyl.
- 16. The diagnostic device of claim 12 wherein R<sup>2</sup> is selected from the group consisting of nitro, benzene sulfonyl and derivatives, tosyl, carbobenzyloxy and derivatives, and benzoyl and derivatives.
- The diagnostic device of claim 12 wherein R<sup>3</sup> comprises a heterocyclic aromatic moiety.
- $\label{eq:controller} \textbf{18.} \qquad \text{The diagnostic device of claim 17 wherein $\mathbb{R}^3$ is a fused ring system.}$ 
  - 19. The diagnostic device of claim 12 wherein R³ is carbocyclic.
- 20. The diagnostic device of claim 19 wherein R³ is 1-naththol and derivatives thereof.
- 21. The diagnostic device of claim 12 wherein R<sup>3</sup> is selected from the group consisting of phenylpyrrole and derivatives thereof, coumarin and derivatives thereof, phenylthiophene and derivatives thereof, indole and derivatives thereof, and 2-phenyl-5H-thiazol and derivatives thereof.

25

5

- The diagnostic device of claim 12 wherein the carrier matrix is 22 filter paper.
- The diagnostic device of claim 12 wherein the carrier matrix 23. contains a diazonium salt.
- 24. The diagnostic device of claim 23 wherein R3-OH reacts with a diazonium salt to form a visible color.
  - The diagnostic device of claim 23 wherein the diazonium salt has the structure:

wherein R4 is aryl; and wherein An is an anion.

- The diagnostic device of claim 25 wherein R4 is 26. morpholinobenzene and derivatives thereof.
- The diagnostic device of claim 23 wherein the diazonium salt is a zwitter ion having the structure

$$G \xrightarrow{N_2^+} D^-$$

wherein D is an anion;

wherein G is independently H, C<sub>1-6</sub> alkyl, or in which the two G mojeties together form a fused ring system; and

wherein B is H or OH.

The diagnostic device of claim 12 wherein R3-OH is optically distinct from the compound of formula (I).

MSE 2609

15

29. A method of preparing a diagnostic device, the device comprising a carrier matrix and a trypsin substrate of formula (I)

$$R^3$$
 $R^3$ 
 $R^4$ 
 $R^2$ 
 $R^2$ 
 $R^3$ 
 $R^4$ 
 $R^4$ 
 $R^4$ 
 $R^4$ 
 $R^4$ 
 $R^4$ 
 $R^4$ 

wherein  $R^1$  is a protecting group for  $N\alpha$ ;  $R^2$  is a protecting group for  $N_G$ ; and  $R^3$  is aryl; and

wherein the compound of formula (I) is a trypsin substrate such that trypsin cleaves the O-C single bond, which liberates R³-OH;

the method comprising:

- (a) contacting a carrier matrix with a buffer solution;
- (b) drying the carrier matrix; and
- (c) contacting the carrier matrix with a solution comprising the trypsin substrate of formula (I).
- 30. The method of claim 29 further comprising (d) drying the carrier matrix.
  - 31. The method of claim 29 wherein the carrier matrix is filter paper.
- 32. The method of claim 29 wherein the carrier matrix comprises a diazonium salt.

MSE 2609

10

- 33. The method of claim 32 wherein R<sup>3</sup>-OH reacts with the diazonium salt to form a visible color.
- 34. The method of claim 25 wherein the solution comprising the trypsin substrate of formula (I) further comprises a diazonium salt.
- 35. The method of claim 29 wherein R³-OH reacts with the diazonium salt to form a visible color.
- 36. The method of claim 29 wherein R³-OH is optically distinct from the compound of formula (I).
- 37. A method for detecting levels of urinary trypsin inhibitor in a biological sample comprising:

contacting a biological sample with a predetermined amount of trypsin, a predetermined amount of a diazonium salt, and a diagnostic device comprising a trypsin substrate of the formula (I)

$$R^3$$
 $HN$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 

wherein  $R^1$  is a protecting group for  $N\alpha$ ;

R2 is a protecting group for NG; and

R3 is aryl; and

wherein the compound of formula (I) is a trypsin substrate such that trypsin cleaves the O-C single bond, which liberates R³-OH; and

MSF 2609

wherein the compound R<sup>9</sup>-OH reacts with a diazonium salt to form a visible color such that the greater the intensity of the color, the less urinary trypsin inhibitor is in the biological sample.

- 38. A diagnostic kit for determining the presence of urinary trypsin inhibitor in a biological fluid, the kit comprising:
  - (a) trypsin; and
  - (b) a trypsin substrate of the formula (I)

$$R^3$$

$$HN$$

$$R^2HN_G$$
(1)

wherein  $R^1$  is a protecting group for  $N\alpha$ ;

R<sup>2</sup> is a protecting group for N<sub>G</sub>; and

R3 is aryl; and

wherein the compound of formula (I) is a trypsin substrate such that trypsin cleaves the O-C single bond, which liberates  $R^3$ -OH.

- 39. The diagnostic kit of claim 38 wherein  ${\sf R}^3\text{-OH}$  is optically distinct from the trypsin substrate.
- 40. The diagnostic kit of claim 38 wherein further comprising: (c) at least one reagent capable of being used to determine the presence of urinary trypsin inhibitor.

MSE 2609

10

5

41. The diagnostic kit of claim 40 wherein the reagent is a diazonium salt.